BCG vaccination with adjunctive APRIL immunotherapy reduces tuberculosis relapse in mice.

Authors

Chen-Yu Tsai, Min Xie, Melissa Cristaldo, Gabriella R Peluso, Joshua Woo, Frank Nuritdinov, Narineh M Odjourian, Maureen Dougher, Rosleine Antilus-Sainte, Kaj M Kreutzfeldt, Sabine Ehrt, Martin Gengenbacher

Published in

The Journal of infectious diseases. Aug 12, 2026. Epub Aug 12, 2026.

Abstract

Bacille Calmette-Guérin (BCG) provides limited protection against tuberculosis relapse. We investigated whether adjunctive immunotherapy targeting B cells enhances BCG-mediated protection in a murine model of latent tuberculosis. While BCG alone had modest effects, adjunctive immunotherapy with recombinant APRIL significantly reduced relapse. Protection was associated with selective remodeling and activation of marginal-zone B cell compartments, whereas effects on T cell populations were comparatively modest. These findings support further investigation of B cell-targeted immunomodulation to improve durable immune control and reduce tuberculosis relapse.

PMID:
42585592
Bibliographic data and abstract were imported from PubMed on 13 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.